Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Halpern

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Patient Preference and Adherence|March 23, 2011
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisRachel Halpern, Sonalee Agarwal, Carole Dembek, et al.
Advances in Therapy|August 27, 2011
Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysisRachel Halpern, Sonalee Agarwal, Leigh Borton, et al.
International Journal of Geriatric Psychiatry|November 16, 2018
Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementiaRachel Halpern, Jerald Seare, Junliang Tong, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
Comparison of Real-world Outcomes Between Patients Treated with Tapentadol ER or Oxycodone CRMike Durkin, Jacqueline Pesa, Jessica Lopatto, et al.
Pain Practice : the Official Journal of World Institute of Pain|October 8, 2015
Evaluating Guideline-recommended Pain Medication Use Among Patients with Newly Diagnosed FibromyalgiaRachel Halpern, Sonali N Shah, Joseph C Cappelleri, et al.
Journal of Managed Care & Specialty Pharmacy|March 26, 2016
Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care CostsCarolyn Martin, Kevin Odell, Joseph C Cappelleri, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|May 8, 2013
Adherence associated with oral medications in the treatment of spasticityRachel Halpern, Patrick Gillard, Glenn D Graham, et al.
Journal of Medical Economics|April 28, 2020
Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United StatesJacqueline Nicholas, Rachel Halpern, Marina Ziehn, et al.
The Primary Care Companion for CNS Disorders|June 8, 2017
Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United StatesMauricio Tohen, Daisy Ng-Mak, Krithika Rajagopalan, et al.
Current Medical Research and Opinion|June 3, 2009
Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysisRachel Halpern, Reema R Mody, Mahesh J Fuldeore, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Patient Preference and Adherence|March 23, 2011
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisRachel Halpern, Sonalee Agarwal, Carole Dembek, et al.
Advances in Therapy|August 27, 2011
Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysisRachel Halpern, Sonalee Agarwal, Leigh Borton, et al.
International Journal of Geriatric Psychiatry|November 16, 2018
Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementiaRachel Halpern, Jerald Seare, Junliang Tong, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
Comparison of Real-world Outcomes Between Patients Treated with Tapentadol ER or Oxycodone CRMike Durkin, Jacqueline Pesa, Jessica Lopatto, et al.
Pain Practice : the Official Journal of World Institute of Pain|October 8, 2015
Evaluating Guideline-recommended Pain Medication Use Among Patients with Newly Diagnosed FibromyalgiaRachel Halpern, Sonali N Shah, Joseph C Cappelleri, et al.
Journal of Managed Care & Specialty Pharmacy|March 26, 2016
Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care CostsCarolyn Martin, Kevin Odell, Joseph C Cappelleri, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|May 8, 2013
Adherence associated with oral medications in the treatment of spasticityRachel Halpern, Patrick Gillard, Glenn D Graham, et al.
Journal of Medical Economics|April 28, 2020
Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United StatesJacqueline Nicholas, Rachel Halpern, Marina Ziehn, et al.
The Primary Care Companion for CNS Disorders|June 8, 2017
Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United StatesMauricio Tohen, Daisy Ng-Mak, Krithika Rajagopalan, et al.
Current Medical Research and Opinion|June 3, 2009
Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysisRachel Halpern, Reema R Mody, Mahesh J Fuldeore, et al.
Pageof 4